Atrioventricular (AV) heart block is a rare but significant adverse effect associated with the use of carbamazepine, a commonly prescribed antiepileptic medication. This abstract provides an overview of the mechanisms underlying carbamazepine-induced AV heart block, as well as management strategies for affected patients. The proposed mechanisms include direct effects on cardiac conduction pathways, alterations in electrolyte balance, and possible drug-drug interactions that may exacerbate cardiac conduction abnormalities. Clinically, patients may present with symptoms ranging from mild dizziness to severe syncope, necessitating timely diagnosis and intervention. Management strategies include discontinuation of carbamazepine, close monitoring of cardiac function, and potential use of temporary pacing in cases of significant AV block. This review aims to enhance awareness of this serious complication among healthcare professionals and underscores the importance of careful monitoring of cardiac function in patients receiving carbamazepine therapy. By understanding the mechanisms and appropriate management strategies, clinicians can improve patient outcomes and reduce the risk of life-threatening arrhythmias.

Carbamazepine, Atrioventricular Heart Block, Cardiac Conduction

Steiner C, Wit AL, Weiss MB, Damato AN. The antiarrhythmic actions of carbamazepine (Tegretol). JPharmacol Exp Ther 1970;173:323–35.

Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adín J. Ion channels andepilepsy.2005;11:1975–2003.

Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepineinduced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992;152:186–91

Ide A, Kamijo Y. Intermittent complete atrioventricular block after long term low-dose carbamazepinetherapy with a serum concentration less than the therapeutic level. Intern Med 2007;46:627–9

Labrecque J, Coté MA, Vincent P. Carbamazepine-induced atrioventricular block. AmJ Psychiatry1992;149:572–3